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Background: Peritumoral activated hepatic stellate cells (HSCs) are versatile myofibroblast-like cells closely related
with hepatocellular carcinoma (HCC) progression. So far, comprehensive comparison of gene expression of human
HSCs during hepatocarcinogenesis is scanty. Therefore, we identified the phenotypic and genomic characteristics of
peritumoral HSCs to explore the valuable information on the prognosis and therapeutic targets of HBV related HCC.
Methods: A tissue microarray containing 224 HBV related HCC patients was used to evaluate the expression of
phenotype markers of HSCs including α-SMA, glial fibrillary acidic protein (GFAP), desmin, vinculin and vimentin.
HSCs and cancer associated myofibroblasts (CAMFs) were isolated from normal, peritumoral human livers and
cancer tissues, respectively. Flow cytometry and gene microarray analysis were performed to evaluate the
phenotypic changes and gene expression in HCC, respectively.
Results: Peritumoral α-SMA positive HSCs showed the prognostic value in time to recurrence (TTR) and overall
survival (OS) of HCC patients, especially in early recurrence and AFP-normal HCC patients. Expression of GFAP
positive HSCs cell lines LX-2 was significantly decreased after stimulation with tumor conditioned medium.
Compared with quiescent HSCs, peritumoral HSCs and intratumoral CAMFs expressed considerable up- and down-
regulated genes associated with biological process, cellular component, molecular function and signaling pathways
involved in fibrogenesis, inflammation and progress of cancer.
Conclusions: Peritumoral activated HSCs displayed prognostic value in HBV related-HCC, and their genomic
characteristics could present rational biomarkers for HCC risk and promising therapeutic targets.
Keywords: Hepatic stellate cell, Prognosis, Phenotype, Gene expression, Hepatocellular carcinomaBackground
Cancer is now recognized as a functional organ caused by
deregulated oncogenes including proto-oncogenes and
tumor-suppress or anti-oncogenes, which may well con-
tribute to certain mutational events in the cancer pheno-
type [1,2]. Indeed, equally numerous reports have indicated
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reproduction in any medium, provided the orshared the capacity to induce genetic instability or muta-
tion and subsequently fostered the carcinogenic process
[3,4]. Therefore, genetic events and phenotypic variation
have shed new light on the relationship between inflam-
mation and cancer. Typically, hepatocellular carcinoma
(HCC) is a malignancy characterized by a high degree of
genetic heterogeneity and often associated with hepatitis
viral infection and cirrhosis [5,6]. Of note, some immune/
inflammation-related gene signatures were identified as
sensitive “readout” screening for high-risk patients likely to
experience HCC recurrence after resection [7,8]. Moreover,
a subtype of human HCC sharing a gene expression pat-
tern with fetal hepatoblasts has been linked to poor prog-
nosis, which was supposed to be derived from hepatic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Peritumoral α-SMA expression according to







(cell numbers > 72)
p
Gender Male 40 152 0.342
Female 4 28
Age(years) ≤51 24 94 0.867
>51 20 86
ALT(U/L) ≤75 35 162 0.700
>75 9 18
AFP(ng/ml) ≤20 18 68 0.731
>20 26 112




Yes 8 46 0.446
No 36 134
Encapsulation Yes 24 96 1.000
No 20 84
Number Single 37 155 0.810
Multiple 7 25
Size ≤5 38 122 0.015
>5 6 58
Differentiation I-II 41 128 0.002
III-IV 3 52
TNM stage I 37 121 0.028
II-III 7 59
α-SMA: α-smooth muscle actin; AFP: alpha fetoprotein; ALT, alanine
aminotransferase; TNM, tumor-node-metastasis.
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logical phenotypes may result from activation of different
oncogenic pathways during tumorigenesis and/or different
cells of origin including activated inflammatory cells, like
tumor-associated macrophages [10], neutrophils [11] and
mast cells [12], which may acquire more potent tumor-
promoting activities and result in dismal outcome of HCC.
Thus, regulation of gene levels in tumor activated inflam-
matory cells could provide crucial information on the pro-
gress and prognosis of HCC.
Interestingly, hepatic stellate cells (HSCs), myofibroblast-
like inflammatory cells under activated state, display plas-
tic phenotypes and properties of progenitor cells [13,14].
In a most recent study [15], we found triggering receptor
expressed on myeloid cells (TREM)-1, a potential func-
tional gene in HSCs, enhanced the aggressiveness of HCC
cells. Moreover, we have previously demonstrated [16]
that the density of peritumoral activated HSCs, including
their putative functional genes (SPARC, TNC and FAP),
were selectively associated with poor prognosis of HCC,
revealing that HSCs could reroute the direction from pro-
inflammatory response to promoting tumor. Furthermore,
a recent integrative genomic analysis revealed that hepa-
toma cells induced the functional deregulation of relevant
gene networks in HSCs, which correlated to the poor out-
come of HCC patients [17]. Also, considerable changed
gene expression signatures of activated HSCs have been
confirmed to have specific contribution to cirrhosis
[18-20] and HCC [21]. However, so far, less attention has
been paid on the comprehensive comparison of gene ex-
pression of human HSCs during hepatocarcinogenesis.
Here, we depicted that peritumoral HSCs were un-
favorable predictors in HBV related HCC following re-
section, especially in early recurrence and AFP-normal
HCC patients. To specifically address the possible hete-
rozygous effects and the functional impact of activated
HSCs in the aggressive phenotype of HCC, we also cha-
racterize the gene expression profile of peritumoral hu-
man HSCs and observed numerous regulated genes
potentially influencing the malignant behavior of acti-
vated HSCs. These alterations presented potential bio-
markers and therapeutic targets to interrupt the pivotal
pathways in HCC development.
Material and methods
Patients and specimens
We randomly selected 224 untreated HCC patients from
2007 who all had hepatitis B history and complete
follow-up data until January 2012 (Table 1). Peritumoral
hepatic tissues and matched tumor samples from 3 HBV
related HCC patients as well as normal tissues from 3
hepatic hemangiomas patients with resection indications
and without HBV infection were used for the isolation
of HSCs/CAMFs. All samples were anonymously codedin this study complied with the Ethics Review Commit-
tee of Zhongshan hospital of Fudan university. Written
informed consent was obtained from all clinical patients
involved in this study. We excluded patients with acute
infection from this study.
Tissue microarray design and immunohistochemistry
A tissue microarray (TMA) was constructed and immu-
nohistochemistry was carried out as described previously
[15,22]. Under low-power magnification (100X), positive
staining cells were screened and photographs of four
representative fields were captured under high-power
magnification (400X) in Leica DMLA light microscope
(Leica Microsystems, Wetzlar, Germany). The positive
cell density of each core was counted by two indepen-
dent investigators blind to clinical outcome and know-
ledge of the clinicopathologic data. Data were expressed
as mean value (±SE) of the triplicate cores taken from
each patient. Primary antibodies were mouse anti-
human monoclonal antibodies combined with α-SMA
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1:100; Cell signaling), desmin (1:50; DAKO), vinculin
(1:200; Upstate, Millipore) and vimentin (1:100; Sigma-
Aldrich), respectively.
Collection of tumor conditioned medium (TCM) and
generation of tumor-induced activated HSCs in vitro
As described previously [15], tumor conditioned medium
(TCM) was collected from HCC cell lines MHCC97L,
HCCLM3 and HCCLM6, respectively. Briefly, 5 × 106
tumor cells were seeded into 100-mm dishes containing
10 mL of DMEM with 10% fetal bovine serum for 24 hours
and thereafter washed twice with serum-free DMEM, and
then cultured in serum-free DMEM. After another
24 hours, the supernatant was centrifuged, filtered and
stored at −20°C until use. HSC cell line LX-2 was cultured
in T25 flasks (0.6x106) with 5 ml TCM supplemented with
5% FBS for 24 hours.
Flow cytometric analysis
According to previous report [18,23], four identified
phenotypes of activated HSCs including GFAP, fibronec-
tin, CD56 and IL-17R (antibody from ebioscinece, Santa
Cruze and R&D Systems, respectively) were used for
flow cytometric analysis. Nonspecific IgG of the corres-
ponding class was used as the negative control.
Isolation and culture of cells
HSCs/myofibroblasts were isolated as our described pre-
viously [15]. We isolated HSCs from surgical peritumo-
ral tissues and CAMFs from matched cancer tissues,
respectively. Quiescent HSCs were isolated from normal
liver tissues from hepatic hemangiomas and prolong cul-
ture cells were used as in vitro activated HSCs. HSCs/
myofibroblasts were isolated by collagenase-pronase
perfusion and subsequent density centrifugation on
Nycodenz gradients. After collagenase-pronase digestion,
the resulting cell pellets were centrifuged at 50 g for
2 minutes to remove hepatocytes. Before collecting
HSCs/CAMFs, obtained cells were seeded for 15 min in
serum free medium to allow Kupffer cells attachment.
To further purify non-attached cells, magnetic anti-
CD45 beads (MACS, Miltenyi Biotec, Germany) were
used to deplete contaminating leucocytes. Peritumoral
HSCs and intratumoral CAMFs were studied at 24 hours
after isolation. HSCs from normal livers were studied at
24 hours after isolation (quiescent HSCs) or after 10 days
culture (in vitro activated HSCs) without passage,
respectively. CD45 and CD31 positive cells were not
found in isolated cells by immunocytochemistry staining,
demonstrating no contaminating pan-leucocytes and
endothelial cells. HSCs purity was assessed by the auto-
fluorescence property and morphology, the populations
were more than 95% pure. Primary cells, HSC cell linesLX-2 (as gifts by professor Jin-sheng Guo in Zhongshan
hospital) and three HCC cell lines (MHCC97L, HCCLM3,
and HCCLM6) initially established and preserved by our
institute [24] were cultured in DMEM supplemented with
10% fetal calf serum (FCS) and 1% penicillin-streptomycin
in 95% air and 5% CO2 at 37°C.
Gene expression analysis
Total RNA was extracted from HSCs/CAMFs for micro-
array analysis. Microarray hybridization was performed
using whole human genome oligo array (4 × 44K, Agilent
Technologies) based on the manufacturer’s standard pro-
tocol. Differentially expressed genes with statistical signifi-
cance between two groups were identified through
volcano plot filtering. The threshold is fold change ≥2.0,
p-value <0.05. Pathway analysis and gene ontology (GO)
analysis were applied. Finally, hierarchical clustering was
performed to show the distinguishable gene expression
pattern among samples.
Quantitative polymerase chain (qPCR) reaction validation
of microarray data
A total of 49 genes were confirmed by qPCR as previous
protocol [16] using commercially available primer-probe
sets (Applied Biosystems, Foster City, CA) and SYBR
Green PCR Master Mix (SABiosciences). Primers for
these genes are listed in Additional file 1. Expression of
GAPDH was used as an internal control. The gene ex-
pression was quantified by the 2-△△CT method.
Statistic analysis
Statistical analysis was performed by Student t test, Fisher’s
exact tests, χ2 tests, Spearman ρ coefficients tests. The
“minimum p value” approach [11,12] was used to get an
optimal cut-off (high α-SMA expression >72) by X-tile 3.6.1
software (Yale University, New Haven, CT, USA). P < 0.05
was considered statistically significant.
Results
Expression and predictive value of distinct phenotype
markers of HSCs in HCC
Desmin and GFAP were both negatively expressed in all
tissue sections. Vinculin and vimentin were expressed
ubiquitously on stromal cells and parenchymal cells and
no predictive value was found in HCC patients. Consist
with previous data [15,16], peritumoral α-SMA was sig-
nificantly related with poor prognosis of these HBV re-
lated HCC patients (cut-off: low ≤ 72, high >72, Figure 1
and Table 2). Moreover, peritumoral α-SMA was associ-
ated with tumor size, tumor differentiation and TNM
stage. On univariate analysis, vascular invasion, TNM
stage as well as peritumoral α-SMA showed prognostic
values for both time to recurrence (TTR) and overall
Figure 1 Images of immunostained cells, HE stain and survival curves for univariate analyses. a-l showed vinculin, vimentin and α-SMA
staining cells in intratumoral (a, b, e, f, i and j) and peritumoral areas (c, d, g, h, k and l), respectively (x 200). a, c, e, g, i and k were negative
controls. m and n showed HE stain in intratumoral (m) and peritumoral areas (n), respectively (x 200). High density of peritumoral α-SMA was
related to decreased OS (o) and TTR (p).
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with OS, while AFP and tumor encapsulation can pre-
dict TTR, not OS. Then, multivariate analysis was fur-
ther performed. In addition to peritumoral α-SMA,
TNM stage was demonstrated to be related with OS
(P = 0.029 and 0.002, respectively) and TTR (P = 0.040
and 0.018, respectively). Significantly, the predictive sig-




AFP (≤20 v >20 ng/ml) NS
Tumor number (single v multiple) 0.032 2.199(1.209-
Vascular invasion(yes v no) 0.008
Tumor encapsulation (yes v no) NS
TNM stage (IvII- III) 0.001 2.175(1.326-
Peritumoral α-SMA density (low v high) 0.013 2.559(1.101-
Univariate analysis: Kaplan-Meier method; multivariate analysis: Cox proportional ha
recurrence; HR: Hazard Ratio; CI: confidence interval; AFP: alpha fetoprotein; TNM: tu
not significant.recurrence (≤ 24 months, Table 3) [15] and AFP-normal
subgroups (P = 0.014 for OS; P = 0.013 for TTR).
Secretion of HCC cells lines partly affected the phenotype
modulation of HSCs
Investigated phenotype markers of HSCs showed com-
pletely different expression patterns in HCC tissues.
Thus, flow cytometric analysis was use to furtherTTR
ltivariate Univariate Multivariate
CI) P P HR (95% CI) P
NA 0.018 NS
4.003) 0.010 NS NA
NS 0.014 1.690(1.011-2.823) 0.045
NA 0.048 NS
3.566) 0.002 0.004 1.834(1.111-3.028) 0.018
5.949) 0.029 0.001 2.424(1.040-5.650) 0.040
zards regression model. Abbreviations: OS: overall survival; TTR: time to
mor-node-metastasis; α-SMA: α-smooth muscle actin; NA: not adopted; NS:
Table 3 Prognostic factors for early and late recurrence
Factor Early recurrence Late recurrence
Univariate Multivariate Univariate Multivariate
P HR (95% CI) P P HR (95% CI) P
AFP(ng/ml)(≤20 v >20) 0.006 1.752(1.035-2.966) 0.037 NS NA
Tumor size (≤5.0 v >5.0) <0.001 2.591(1.631-4.116) <0.001 NS NA
Vascular invasion(yes v no) 0.011 NS NS NA
TNM stage (IvII- III) 0.012 NS NS NA
Peritumoral α-SMA density (low v high) 0.002 3.148(1.263-7.844) 0.014 NS NA
Univariate analysis: Kaplan-Meier method; multivariate analysis: Cox proportional hazards regression model. Abbreviations: HR: Hazard Ratio; CI: confidence
interval; AFP: alpha fetoprotein; TNM: tumor-node-metastasis; α-SMA: α-smooth muscle actin; NA: not adopted; NS: not significant.
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response to HCC cells stimulation in vitro. Strikingly,
similar to the results of immunohistochemistry, the fre-
quency of GFAP+ HSCs was decreased exposed to TCM
from HCC cell lines MHCC97L, HCCLM3 and HCCLM6
(Figure 2, P < 0.01). Other investigated biomarkers showed
no significance.
Global comparison in gene expression between different
activated/quiescent phenotypes of HSCs and CAMFs
Expression levels of 17160 genes were compared between
quiescent and activated HSCs and CAMFs from three inde-
pendent samples per group. Among all significant changed
genes (≥2-fold change and p <0.05), there were only 188
upregulated and 467 downregulated genes in peritumoral
HSCs compared to intratumoral CAMFs which were from
the same HCC patients. Notably, compared with quiescent
phenotype HSCs, the same patients-derived culture-
activated HSCs yielded as many as 1485 upregulated and
1471 downregulated genes. We found the most significant
change happened between peritumoral HSCs/intratumoral
CAMFs and culture-activated HSCs (4479 and 3540
upregulated genes, and 3691 and 3380 downregulated
genes, respectively) rather than between peritumoral
HSCs/intratumoral CAMFs and quiescent phenotype HSCs
(1032 and 994 upregulated genes, and 1654 and 1188
downregulated genes, respectively, Figure 3). The levels of
correlation between two independent cell populations also
displayed these kinds of changes (Additional file 2). Next,
we performed a functional analysis associating differentially
expressed genes with GO categories, which covered three
domains: biological process, cellular component and mole-
cular function. Compared with quiescent HSCs, upre-
gulated genes in peritumoral HSCs and intratumoral
CAMFs were investigated to search potential protumor
genes (Additional file 3, P < 0.001). In biological process,
cell adhesion (e.g. CD209, collagen, type XII, alpha 1), cel-
lular lipid metabolic process (e.g. catalase, platelet-derived
growth factor alpha) and other processes related genes
were upregulated in peritumoral HSCs and intratumoral
CAMFs. Cellular component includes cytoplasmic part(e.g. enolase 2, glucuronic acid epimerase), contractile fiber
(e.g. vinculin, matrix metallopeptidase 2), among others.
Molecular function consists of protein binding (e.g. vascu-
lar endothelial growth factor A, transforming growth factor
beta 1), growth factor binding (e.g. oncostatin M receptor,
insulin-like growth factor binding protein 6) and so on.
Finally, base on the latest KEGG (Kyoto Encyclopedia of
Genes and Genomes, http://www.genome.jp/kegg) data-
base, we performed pathway analysis by differentially
expressed genes. The p-value (<0.05) denotes the signifi-
cance of the pathway correlated to the conditions. Lower
the p-value, more significant is the pathway. Of note, sev-
eral well-known pathways in development of HCC such as
VEGF [25] (e.g. mitogen-activated protein kinase 13, pro-
tein kinase C, beta) and p53 [25] (e.g. cyclin-dependent
kinase 6, insulin-like growth factor binding protein 3) sig-
naling pathway related genes were changed significantly in
comparison between peritumoral HSCs and CAMFs
(Figure 4 and Additional file 4).
Verification of the DNA microarray results
To validate the results of DNA microarray, some identi-
fied genes of interest involved in liver fibrogenesis and
hepatocarcinogenesis were assessed by qRT-PCR. Similar
up- and down- regulated trends with DNA microarray
were detected in the genes encoding key molecules impli-
cated in inflammation (e.g. IL-17RA, TLR-2), tumor inva-
sion and metastasis (e.g. MMP25), adhesion (e.g. CD36,
VCAM1), extracellular matrix degradation (e.g. TIMP2),
cytoskeletal organization (e.g. ACTG2, ACTA2). Other
genes (e.g. COL1A2, MMP1, GK, PPARG) associated with
certain pathways such as ECM-receptor interaction and
PPAR signaling pathway also confirmed the results
obtained in DNA microarray (Additional file 5).
Discussion
The plasticity of HSCs phenotype and the lack of spe-
cific marker proteins hampered an in depth analysis of
the nature and functional properties of these fibroblastic
cells in human normal and diseased liver. In particular,
Figure 2 The frequency of GFAP+ hepatic stellate cells (HSCs) after stimulation with tumor conditioned medium (TCM) from
hepatocellular carcinoma (HCC) cell lines MHCC97L, HCCLM3 and HCCLM6 which was determined by flow cytometry. The relative
quantitation was also shown. *P <0.01 compared with HSCs exposed to TCM from HCC cell lines.
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present in HCC was seldom noticed. In this present
study, our immunohistochemical analysis displayed va-
rious distribution and expression intensity of four most
prominent HSCs phenotype/gene markers including
α-SMA, desmin, GFAP and vimentin [14] as well as a re-
cently reported marker vinculin [26], which probably
exhibited their different in vivo biological behaviors and
cellular response to injurious stimuli in the progress of
HCC. Although desmin and GFAP were markers of rat/
mouse HSCs [14,27] and GFAP has also been identifiedas an early marker of human HSCs activation [28,29], our
study showed they were not expressed in human HCC
tissues. Also, vimentin and vinculin were not specific
markers for human HSCs, at least in HCC. These results
suggested the complexity and the difference of HCC mi-
lieu compared to other chronic liver diseases. Excitedly, as
a canonical marker of activated HSCs, high expression of
α-SMA still showed specificity in HSCs and a good prog-
nostic performance in HBV related HCC patients, which
therefore could provide us a reliable monitoring indicator
in at-risk HBV related HCC patients.
Figure 3 Gene expression patterns between peritumoral activated hepatic stellate cells (pHSCs), intratumoral cancer associated
myofibroblasts (CAMFs), culture-activated HSCs (aHSCs) and quiescence HSCs (qHSCs), respectively. Each panel of 3 separate cell sample
per group (1, 2, and 3) showed hierarchical clustering based on different expression genes represented as a heat map. The Venn plot showed
overlapping patterns of probe sets with ≥2-fold up-regulated or down-regulated genes (P < 0.05) in pHSCs (P), CAMFs (T) and aHSCs (A)
compared with aHSCs (Q). The number shown in the shared areas represented the common entities.
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HSCs were demonstrated as independent predictors for
HCC patients with higher recurrence rate and reduced sur-
vival times, also closely related to adverse HCC cha-
racteristics like tumor size, tumor differentiation and TNM
stage. These data supported the protumor function of acti-
vated HSCs. A more important finding was observed that
peritumoral HSCs served as unfavorable prognostic predic-
tors in several subgroups including early recurrence group
(≤ 24 months) [15] and AFP-normal patients in HBV re-
lated HCC. These results implied activated HSCs could
participate in intrahepatic metastases probably involved in
the conversion of pro-inflammatory response into promot-
ing tumor [15]. Furthermore, for the AFP-normal HCC pa-
tients who were difficult to be supervised, peritumoral
HSCs were potential monitoring indicators because of their
better prognostic values in the AFP-normal group.In HCC tissues, different expression patterns of pheno-
type markers of HSCs probably were cellular response to
long-term injurious stimuli in HCC microenvironment.
Thus, the early effects of HCC on HSCs (HSC cell line
LX-2) were further evaluated by flow cytometry. Here,
GFAP showed decreased expression in LX-2 after tumor
stimulation, which can partly interpret its transform from
an activated marker in chronic liver disease [28,29] to
negative expression in HCC tissues. Moreover, GFAP was
identified as a tumor suppressor gene in astrocytoma [30]
and glioma pathogenesis [31]. Loss of GFAP expression in
tumor progression could be secondary loss of a differen-
tiation marker and represented a step in tumor develop-
ment [32].
On base of the clinical analysis results as aforemen-
tioned, we conjectured that there could be more potential
key molecules or genes in HSCs which were related with
Figure 4 Pathway analysis showed functional networks identified between peritumoral (P) activated hepatic stellate cells (HSCs) and
intratumoral myofibroblasts (T). Selected significant canonical pathways associated with PPAR signaling (a, P vs T upregulation) and P53 (b, P vs T
downregulation) were shown, respectively. Yellow, orange and green marked nodes represented down-regulated genes, up-regulated genes and no
significance, respectively.
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during the development of HCC. Although our colleagues
[21] recently assessed the features of rat HSCs cultured in
conditioned medium of HCC cell lines, no study has di-
rectly investigated gene expression patterns of HSCs in
liver specimens from patients with HCC. A number of
genomic analysis of HSCs have been performed, but
majority of these studies were restricted to cirrhosis or
chronic liver diseases induced HSC activation [18-20].
Therefore, we investigated gene expression of primary
HSCs/CAMFs from normal, peritumoral and intratumoral
livers. Detailed genomic analysis will contribute to study
of their different roles during hepatocarcinogenesis.
To our knowledge, this is the first study about gene ex-
pression profile of HSCs freshly isolated from human HCC
tissues. COL1A2, ACTG2 and ACTA2, as typical HSC or
myofibroblast-like cell activation markers, were increased
significantly in activated HSCs and CAMFs compared to
quiescent HSCs. These findings, as well as the validated
genes suggested the reliability of DNA microarrays data.
Moreover, high correlation coefficients between the same
types of cells demonstrated small gene expression variances
in each group (Additional file 2: Table S2). Consistent with
previous studies [18,20], lower correlation coefficients be-
tween culture-activated HSCs and in vivo activated HSCs/
CAMF suggested culture-activated HSCs can only partly
reflect the underlying gene expression changes of in vivo
activated HSCs. Compared with in vivo activated HSCs/
CAMFs, different gene expression patterns were detected
in culture-activated HSCs probably due to different in vivo
stimulus effects and the lack of cell-cell contact and cell–
matrix interaction [18]. Importantly, our study identified a
large number of previously known and unknown functional
genes in activated HSCs/CAMFs during the process of
hepatocarcinogenesis. First, peritumoral HSCs and intra-
tumoral CAMFs shared similar gene expression profile
(r = 0.936, P < 0.001) and relatively minor gene changes in
HCC, which therefore suggested the important roles of
these changed genes in hepatocarcinogenesis and the pos-
sible evolution from HSCs into myofibroblasts. Compared
with upregulated genes, more downregulated genes (188 v
467) in intratumoral CAMFs than peritumoral HSCs may
be associated with loss-of-function mutation of genes in
intratumoral immunosuppression microenvironments. Se-
cond, according to biological process in GO analysis, con-
siderable inflammation/immune response related genes
(e.g. IL-18, TNFRSF1B) upregulated in peritumoral HSCs
compared with intratumoral CAMFs, indicating activated
HSCs were sensitive target cells respond to peritumoral in-
flammatory stimulus and can be driven into malignant phe-
notypes fostering the carcinogenic process. Third, pathway
analysis of differentially expressed genes further extended
the information on the roles of peritumoral HSCs and
intratumoral CAMFs in development of HCC. For example, compared with quiescent HSCs, down-regulate of
apoptosis related genes in CAMFs may be implicated in
their increased proliferative abilities. Compared to CAMFs,
lower expression levels of genes in p53 pathway in peri-
tumoral HSCs may attribute to the protumor power of
activated HSCs. Fourth, identification of novel genes
associated with tumor activated HSCs can benefit an in
depth analysis of the nature and functional properties
of HSCs in HCC. However, further studies need to test
these hypotheses.
Recent epidemiologic data indicate that one of the
most important risk factors for HCC development is
HBV infection, especially in east Asian [33,34]. Here, in
absence of a direct association between HBV infection
and HSCs activation, but we highlighted HSCs function
as regulators in inflammation-mediated liver injury after
HBV infection. An in-depth comparison with other eti-
ologies including hepatitis C virus or alcohol-related
HCC could find the association between HBV and HSCs
activation. Consist with previous survey [34], our most
tissue samples were obtained from patients with typical
cirrhosis (192/224, Table 1). Accordingly, we conjecture
that cirrhosis might influence the gene expression level
in HSCs to a great extent. Further investigation in HCC
patients with different grades of fibrosis may provide
further insight into the mechanisms of malignant trans-
formation from fibrosis and cirrhosis to HCC.
Conclusions
In conclusion, we demonstrated that peritumoral acti-
vated human HSCs were poor prognostic factors for
HBV related HCC after resection, especially in early re-
currence and AFP-normal subgroups. Moreover, we
showed for the first time that in HCC milieu, peri-
tumoral HSCs markedly expressed fibrogenesis and
hepatocarcinogenesis related genes. In this regards, these
alterations had potential to be responsible for the ac-
quirement of malignant phenotypes and behavior of acti-
vated HSCs during the process of HCC, therefore
providing us available multi-target to constitute a prom-
ising therapeutic strategy for HCC.Additional files
Additional file 1: Table S1. Primers for qRT-PCR.
Additional file 2: Table S2. Spearman rank correlation coefficient on all
targets value.
Additional file 3: Table S3. Representative genes in Gene Ontology
analysis in different cell phenotypes.
Additional file 4: Table S4. Representative genes in pathway analysis
in different cell phenotypes.
Additional file 5: Table S5. qRT–PCR validated genes in Gene
Ontology analysis and pathway analysis in different phenotype cells.
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